Holder Sio Capital Management LLC Has Upped Sage Therapeutics INC (Put) (SAGE) Position

March 14, 2018 - By Stephen Andrade

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.23, from 0.98 in 2017Q2. It is positive, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. Victory holds 0.05% or 331,405 shares. Northern Tru owns 412,174 shares. Oppenheimer Asset, a New York-based fund reported 1,944 shares. Art Advsr Ltd reported 33,800 shares or 0.11% of all its holdings. Wells Fargo And Mn has invested 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Vanguard Gp holds 2.83M shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 1,378 shares. Cubist Systematic Strategies Ltd Llc holds 0% or 1,052 shares. Prudential Financial reported 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Fiduciary Trust has invested 0.03% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Bancorporation Of America De holds 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE) or 100,312 shares. Hershey Tru reported 1,887 shares or 0% of all its holdings. California State Teachers Retirement Sys stated it has 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Amalgamated Fincl Bank reported 4,403 shares. Meeder Asset Mngmt, Ohio-based fund reported 16 shares.

Since December 14, 2017, it had 0 insider purchases, and 3 selling transactions for $27.36 million activity. On Wednesday, January 10 Kanes Stephen sold $7.80 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 44,000 shares. 58,139 shares were sold by PAUL STEVEN M, worth $10.00M.

Sio Capital Management Llc increased its stake in Sage Therapeutics Inc (Put) (SAGE) by 217.33% based on its latest 2017Q3 regulatory filing with the SEC. Sio Capital Management Llc bought 130,400 shares as the company’s stock rose 0.86% with the market. The institutional investor held 190,400 shares of the health care company at the end of 2017Q3, valued at $11.86M, up from 60,000 at the end of the previous reported quarter. Sio Capital Management Llc who had been investing in Sage Therapeutics Inc (Put) for a number of months, seems to be bullish on the $7.96 billion market cap company. The stock decreased 0.05% or $0.08 during the last trading session, reaching $173.83. About 194,088 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since March 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Sio Capital Management Llc, which manages about $116.75 million and $192.73M US Long portfolio, decreased its stake in Sanofi Sa (NYSE:SNY) by 136,523 shares to 45,099 shares, valued at $2.25 million in 2017Q3, according to the filing.

More news for Sage Therapeutics, Inc. (NASDAQ:SAGE) were recently published by: Benzinga.com, which released: “Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy” on February 26, 2018. Businesswire.com‘s article titled: “Sage Therapeutics Announces Fourth Quarter and Full Year 2017 Financial …” and published on February 22, 2018 is yet another important article.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Among 18 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 16 have Buy rating, 0 Sell and 2 Hold. Therefore 89% are positive. SAGE Therapeutics had 55 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by BMO Capital Markets on Wednesday, June 29 with “Outperform”. The firm earned “Buy” rating on Thursday, November 9 by BMO Capital Markets. The company was upgraded on Thursday, December 7 by Chardan Capital Markets. The rating was maintained by RBC Capital Markets with “Buy” on Thursday, February 22. The company was upgraded on Friday, November 10 by Chardan Capital Markets. BMO Capital Markets maintained the shares of SAGE in report on Thursday, December 7 with “Buy” rating. On Tuesday, February 14 the stock rating was upgraded by Chardan Capital Markets to “Neutral”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) earned “Buy” rating by Cowen & Co on Thursday, December 7. The stock has “Buy” rating by Lake Street on Friday, March 11. The firm has “Buy” rating given on Thursday, December 7 by Stifel Nicolaus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: